Demo Sign up Log In

AstraZeneca PLC Ordinary Shares (AZN)

R&D Expenses

$15.07B

TTM · Period ending: Jun 30, 2026 · USD

AZN R&D Expenses

Latest reported$15.07Bperiod endingJun 30, 2026

Latest reported$15.07Bperiod endingJun 30, 2026

AZN TTM R&D Expenses ($0.00 → $15.07B)

TTM R&D Expenses

High-resolution chart · PNG

AZN r&d expenses history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

AstraZeneca PLC Ordinary Shares R&D Expenses — Trailing twelve months (TTM) (USD)
Period ending	R&D Expenses (USD)
Jun 30, 2001	3,023,276,599
Mar 31, 2001	2,968,202,614
Dec 31, 2000	2,894,611,062
Sep 30, 2000	2,784,194,740
Jun 30, 2000	2,819,719,222
Mar 31, 2000	2,861,793,207
Dec 31, 1999	2,265,562,378
Sep 30, 1999	1,320,000,000
Jun 30, 1999	656,000,000
Mar 31, 1999	556,500,000
Dec 31, 1998	556,500,000
Sep 30, 1998	556,500,000
Jun 30, 1998	556,500,000
Mar 31, 1998	0
Dec 31, 1997	0
Sep 30, 1997	0
Jun 30, 1997	0
Mar 31, 1997	0
Dec 31, 1996	0
Sep 30, 1996	0
Jun 30, 1996	0
Mar 31, 1996	0
Dec 31, 1995	0
Sep 30, 1995	0
Jun 30, 1995	0
Mar 31, 1995	0
Dec 31, 1994	0
Sep 30, 1994	0
Jun 30, 1994	0
Mar 31, 1994	0
Dec 31, 1993	0

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.